News | Heart Valve Technology | February 28, 2023

FDA Issues Statement on Abbott Trifecta Valves: Potential Risk of Early Structural Valve Deterioration

The FDA is encouraging you to report adverse events related to Trifecta valves to the FDA.

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to inform healthcare providers about the potential risk of early structural valve deterioration (SVD) with Abbott Trifecta valves, including the Trifecta valve and Trifecta valve with Glide Technology (GT). 

Information from published literature suggests a higher cumulative incidence of early SVD for Trifecta valves compared to other commercially available surgical bioprosthetic valves. In addition, the FDA has received reports describing early SVD. The FDA is working with the manufacturer to evaluate information from all available sources on this issue. 

The FDA is encouraging you to report adverse events related to Trifecta valves to the FDA. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. 

Recommendations 

The FDA recommends that health care providers:  

  • Be aware of the potential risk of early SVD with Trifecta valves, and current patient management considerations, as communicated by Abbott
  • Discuss the risks and benefits of all available aortic valve treatment options with your patients and their caregivers as part of shared clinical decision-making prior to surgery. 
  • Read and carefully follow the Instructions for Use (IFU) when implanting a Trifecta GT valve. 
  • Monitor patients who have undergone implantation with Trifecta valves for signs and symptoms of potential SVD. 
    • Instruct patients to seek medical attention with new onset of symptoms such as shortness of breath or fatigue. 
    • Ensure lifelong follow-up visits, conducted at least yearly, including transthoracic echocardiogram (TTE) assessment of the valve beginning one-year post-implant. 
  • Report any adverse events with Trifecta valves to the FDA.  Refer to the Reporting Problems to the FDA section below. 

Background 

The Trifecta and Trifecta GT valves are heart valve replacement devices intended to treat diseased, damaged, or malfunctioning native or prosthetic aortic heart valves. The first-generation Trifecta valve was first approved in 2011 and is no longer marketed in the U.S. The Trifecta GT valve was approved in 2016. 

The FDA routinely evaluates adverse event reports and published literature to monitor the safety and effectiveness of medical devices. The published literature includes a comparison of durability for Trifecta valves to other commercially available bovine pericardial valves across different timepoints post-implant. Outcomes from these studies suggest a higher cumulative incidence of early SVD and lower freedom from reintervention due to SVD associated with Trifecta valves. The published literature includes results combined for the Trifecta and Trifecta GT valves, and the patient management considerations provided by Abbott apply to both Trifecta valve models.   

The FDA has also received medical device reports (MDRs) that describe early SVD with Trifecta valves, with reports showing a peak time to SVD of three to four years post-implant. Reported outcomes include surgical valve explant/replacement, transcatheter valve-in-valve intervention, and in some cases death. The FDA recognizes the limitations of MDR data, including that incidence cannot be determined from the passive surveillance reporting system. Reports submitted to the FDA are just one source of information that the FDA uses to monitor the safety of medical devices. 

FDA Actions 

The FDA is working with the manufacturer to further evaluate the issue and develop additional patient management strategies, if needed. 

The FDA will continue to monitor the literature and reports of adverse events related to the issue. 

The FDA will inform the public if any significant, new information or recommendations become available. 

Reporting Problems to the FDA 

The FDA encourages health care providers to report any adverse events or suspected adverse events experienced with Abbott Trifecta valves. 

Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. 

Additional Resources 

From Abbott: Important Information Regarding SVD in Trifecta Family of ValvesExternal Link Disclaimer 

Contact Information 

If you have questions about this letter, contact the Division of Industry and Consumer Education (DICE). 


Related Content

News | Structural Heart

September 6, 2023 — The diagnosed severity of aortic stenosis strongly correlates with clinical outcomes, new Kaiser ...

Home September 06, 2023
Home
News | Structural Heart

July 21, 2023 — Onecrea Medical has announced the success of the first-in-human implants of its Transcatheter Aortic ...

Home July 21, 2023
Home
News | Structural Heart

June 22, 2023 — Lankenau Medical Center, part of Main Line Health, has performed the first minimally invasive catheter ...

Home June 22, 2023
Home
News | Structural Heart

June 5, 2023 — Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral ...

Home June 05, 2023
Home
News | Structural Heart

May 24, 2023 — Medtronic announced two-year results of their Harmony Transcatheter Pulmonary Valve (TPV) System, which ...

Home May 24, 2023
Home
News | Structural Heart

May 19, 2023 — Abbott announced late-breaking data that add to the body of clinical evidence supporting the benefits of ...

Home May 19, 2023
Home
News | Structural Heart

May 17, 2023 — Edwards Lifesciences announced that new data from the Benchmark Registry in Europe demonstrated the ...

Home May 17, 2023
Home
News | Structural Heart

March 16, 2023 — Cardiologists at the UW Medicine Heart Institute recently performed a first-in-the-world procedure ...

Home May 16, 2023
Home
News | Structural Heart

May 16, 2023 — Henry Ford Health Interventional cardiologists William O’Neill, M.D., and Khaldoon Alaswad, M.D., took a ...

Home May 16, 2023
Home
News | Structural Heart

May 15, 2023 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 15, 2023
Home
Subscribe Now